EVAX
Evaxion Biotech A/S NASDAQ Listed Feb 5, 2021$4.08
Mkt Cap $25.8M
52w Low $1.43
24.7% of range
52w High $12.15
50d MA $3.90
200d MA $4.31
P/E (TTM)
-3.7x
EV/EBITDA
-1.7x
P/B
1.7x
Debt/Equity
0.4x
ROE
—
P/FCF
-4.6x
RSI (14)
—
ATR (14)
—
Beta
0.20
50d MA
$3.90
200d MA
$4.31
Avg Volume
34.2K
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Dr. Neergaards Vej · Horsholm 2970 · DK
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.24 | -1.00 | -308.2% | 3.40 | -0.9% | -5.3% | -4.3% | +16.2% | +8.1% | +8.0% | — |
| Nov 6, 2025 | AMC | — | 0.73 | — | 6.26 | -1.1% | +1.9% | +0.0% | -6.0% | +0.7% | -5.5% | — |
| Aug 14, 2025 | AMC | -0.50 | -0.76 | -52.0% | 2.86 | +0.0% | +0.7% | +11.8% | -5.6% | -3.0% | +5.1% | — |
| May 27, 2025 | AMC | -0.65 | -0.29 | +55.4% | 2.36 | +3.8% | +11.4% | -12.5% | +7.0% | +10.6% | +0.7% | — |
| Mar 26, 2025 | AMC | -0.26 | -0.80 | -207.7% | 1.77 | +0.0% | -0.6% | +0.0% | +5.1% | -10.3% | +1.8% | — |
| Oct 31, 2024 | AMC | -0.60 | -0.20 | +66.7% | 13.35 | -3.4% | -3.0% | +1.9% | -1.1% | -1.5% | +1.9% | — |
| Aug 14, 2024 | AMC | 0.10 | -0.60 | -700.0% | 13.76 | +8.6% | +10.0% | +6.2% | +5.6% | -5.0% | -0.8% | — |
| May 28, 2024 | AMC | -0.56 | 0.15 | +126.8% | 19.15 | +4.4% | -6.3% | +0.3% | +1.9% | -4.1% | +0.0% | — |
| Mar 27, 2024 | AMC | -1.60 | -0.80 | +50.0% | 15.00 | +0.0% | +6.7% | +0.9% | +20.1% | -7.2% | +1.4% | — |
| Dec 19, 2023 | AMC | -0.19 | -10.50 | -5426.3% | 31.10 | +6.1% | +6.9% | +3.6% | +3.1% | -0.7% | -0.7% | — |
| Aug 18, 2023 | AMC | -0.21 | -10.50 | -4900.0% | 46.00 | +3.3% | +4.9% | +1.6% | +0.0% | -3.5% | -4.8% | — |
| May 31, 2023 | AMC | -0.24 | -12.00 | -4900.0% | 76.00 | +0.0% | -2.0% | -0.7% | +3.4% | -7.8% | -2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.25 | $4.27 | +0.5% | -5.2% | +3.7% | +3.3% | -1.4% | +3.5% |
| Mar 9 | Lake Street | Maintains | Buy → Buy | — | $3.22 | $3.12 | -3.1% | -4.3% | +16.2% | +8.1% | +8.0% | +1.9% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.22 | $3.12 | -3.1% | -4.3% | +16.2% | +8.1% | +8.0% | +1.9% |
| Oct 20 | Lake Street | Maintains | Buy → Buy | — | $6.79 | $7.00 | +3.1% | +4.4% | -7.9% | -16.7% | +3.1% | +5.0% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.79 | $7.00 | +3.1% | +4.4% | -7.9% | -16.7% | +3.1% | +5.0% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.30 | $4.29 | +30.0% | +37.3% | -10.8% | -5.9% | -1.1% | +18.1% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.66 | $1.69 | +1.8% | +1.8% | +0.0% | -10.7% | -4.6% | -4.2% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.55 | $2.50 | -2.0% | +4.3% | -4.9% | -3.6% | -11.1% | +4.1% |
| Feb 4 | Lake Street | Maintains | Buy → Buy | — | $2.40 | $3.93 | +63.8% | +36.2% | -8.6% | -8.0% | -6.2% | +1.6% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.46 | $2.35 | -4.5% | -2.4% | +36.2% | -8.6% | -8.0% | -6.2% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.35 | $12.90 | -3.4% | -3.0% | +1.9% | -1.1% | -1.5% | +1.9% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.15 | $15.00 | +6.0% | +8.1% | +2.0% | -0.3% | -5.8% | +1.7% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.75 | $16.45 | +4.4% | -5.1% | -1.3% | +0.7% | -4.7% | +8.1% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.13 | $15.70 | +3.8% | +6.2% | +5.6% | -4.9% | -0.8% | -4.7% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.10 | $14.50 | +2.8% | +1.8% | -7.7% | -5.7% | +11.4% | -10.3% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.60 | $17.60 | +0.0% | +0.0% | -2.0% | +2.2% | -3.9% | -2.1% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.40 | $19.40 | +0.0% | -7.2% | +1.4% | +1.1% | +10.8% | -3.2% |
| Apr 2 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $16.15 | $17.00 | +5.3% | +20.1% | -7.2% | +1.4% | +1.1% | +10.8% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.35 | $15.20 | -1.0% | -1.3% | +0.7% | +0.0% | +1.6% | +1.0% |
| Dec 21 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $33.25 | $33.50 | +0.8% | +3.6% | +3.1% | -0.7% | -0.7% | +0.0% |
| Mar 30 | Lake Street | Maintains | Buy → Buy | — | $52.50 | $52.50 | +0.0% | +2.4% | +5.1% | +0.9% | +3.5% | -0.8% |
| Nov 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $118.00 | $115.00 | -2.5% | -6.4% | +4.5% | -3.5% | +0.8% | -4.3% |
| Mar 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $354.00 | $377.50 | +6.6% | +9.5% | -8.9% | +0.6% | -1.0% | +7.3% |
No insider trades available.
No recent filings available.
Data updated apr 26, 2026 10:31am
· Source: massive.com